Press release
Masimo Hosts 2025 Investor Day and Details Strategic Roadmap for Durable Growth
Announces Long-Range Targets Including 7% - 10% Revenue CAGR Through 2028 Highlights Clear Focus on Patient Outcomes, Technology Innovation and Commercial
About this update from Masimo Corporation
[{"type":"text","content":"\nAnnounces Long-Range Targets Including 7% - 10% Revenue CAGR Through 2028\n\nHighlights Clear Focus on Patient Outcomes, Technology Innovation and Commercial Execution\n\n IRVINE, Calif.--(BUSINESS WIRE)--\nMasimo (NASDAQ: MASI) today hosted its 2025 Investor Day at the Company’s headquarters. At the event, Masimo’s management team provided an update on the Company’s long-term strategy, including the pathway for expanding Masimo’s position as a global leader in patient monitoring, the Company’s multi-year pipeline, and a clear roadmap to deliver durable revenue growth, margin expansion and increased cash flow. Masimo also provided a detailed look at each of its growth pillars.\n\nThe Company’s updated long-range plan through 2028 includes the following financial targets:\n\n\nRevenue: Compound annual growth rate (CAGR) of 7%-10%\n\n\nOperating Margin: Approximately 30% by 2028\n\n\nAdjusted Earnings Per Share: $8.00 by 2028\n\n\nOperating Cash Flow: Approximately $1 billion cumulatively from 2026-2028\n\n\nMasimo also reaffirmed the 2025 financial guidance it last stated on November 4, including Non-GAAP Revenue of $1,510 - $1,530 million, Non-GAAP operating profit of $412 - $424 million and Non-GAAP earnings per diluted share of $5.40 - $5.55.\n\n“Masimo’s market leading position is driven by our mission to deliver innovations that empower clinicians and transform patient care,” said Katie Szyman, Chief Executive Officer of Masimo. “As we enter this next chapter, we are incredibly well positioned to advance that mission. We have the team, the innovation engine and the clear execution plan to continue building on this success and unlock Masimo’s full potential. Our commitment is to deliver long-term value to patients, shareholders, employees and partners.”\n\nWebcast of Masimo Investor Day\nA replay of the webcast can be accessed through the link below:\nMasimo Investor Day Webcast\n\nAbout Masimo\nMasimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo innovations empower clinicians to transform patient care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform o...